CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab ; volume:22 ; number:1 ; day:15 ; month:4 ; year:2022 ; pages:1-10 ; date:12.2022
BMC cancer ; 22, Heft 1 (15.4.2022), 1-10, 12.2022
- Creator
-
Matsunaga, Tomoyuki
Saito, Hiroaki
Kuroda, Hirohiko
Osaki, Tomohiro
Takahashi, Sadamu
Iwamoto, Akemi
Fukumoto, Yoji
Taniguchi, Kenjiro
Fukuda, Kenji
Miyauchi, Wataru
Shishido, Yuji
Miyatani, Kozo
Fujiwara, Yoshiyuki
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-09482-8
- URN
-
urn:nbn:de:101:1-2022063020080121973421
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Matsunaga, Tomoyuki
- Saito, Hiroaki
- Kuroda, Hirohiko
- Osaki, Tomohiro
- Takahashi, Sadamu
- Iwamoto, Akemi
- Fukumoto, Yoji
- Taniguchi, Kenjiro
- Fukuda, Kenji
- Miyauchi, Wataru
- Shishido, Yuji
- Miyatani, Kozo
- Fujiwara, Yoshiyuki
- SpringerLink (Online service)
Other Objects (12)
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Natural History of Patients with Unresectable Cholangiocarcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Natural History of Patients with Unresectable Cholangiocarcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Natural History of Patients with Unresectable Cholangiocarcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer